Literature DB >> 9490778

Myotonic dystrophy: molecular windows on a complex etiology.

Z Korade-Mirnics1, P Babitzke, E Hoffman.   

Abstract

Myotonic dystrophy (DM) is the most common form of adult onset muscular dystrophy, with an incidence of approximately 1 in 8500 adults. DM is caused by an expanded number of trinucleotide repeats in the 3'-untranslated region (UTR) of a cAMP-dependent protein kinase (DM protein kinase, DMPK). Although a large number of transgenic animals have been generated with different gene constructions and knock-outs, none of them faithfully recapitulates the multisystemic and often severe phenotype seen in human patients. The transgenic data suggest that myotonic dystrophy is not caused simply by a biochemical deficiency or abnormality in the DM kinase gene product. Emerging studies suggest that two novel pathogenetic mechanisms may play a role in the disease: the expanded repeats appear to cause haploinsufficiency of a neighboring homeobox gene and also abnormal DMPK RNA appears to have a detrimental effect on RNA homeostasis. The complex, multisystemic phenotype may reflect an underlying multifaceted molecular pathophysiology: the facial dysmorphology may be due to pattern defects caused by haploinsufficiency of the homeobox gene, while the muscle disease and endocrine abnormalities may be due to both altered RNA metabolism and deficiency of the cAMP DMPK protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9490778      PMCID: PMC147423          DOI: 10.1093/nar/26.6.1363

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  59 in total

1.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts.

Authors:  B M Davis; M E McCurrach; K L Taneja; R H Singer; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Anomalous rapid electrophoretic mobility of DNA containing triplet repeats associated with human disease genes.

Authors:  P D Chastain; E E Eichler; S Kang; D L Nelson; S D Levene; R R Sinden
Journal:  Biochemistry       Date:  1995-12-12       Impact factor: 3.162

3.  Alternative structures in duplex DNA formed within the trinucleotide repeats of the myotonic dystrophy and fragile X loci.

Authors:  C E Pearson; R R Sinden
Journal:  Biochemistry       Date:  1996-04-16       Impact factor: 3.162

4.  Comparison of CTG repeat length expansion and clinical progression of myotonic dystrophy over a five year period.

Authors:  L Martorell; J M Martinez; N Carey; K Johnson; M Baiget
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

5.  Pausing of DNA synthesis in vitro at specific loci in CTG and CGG triplet repeats from human hereditary disease genes.

Authors:  S Kang; K Ohshima; M Shimizu; S Amirhaeri; R D Wells
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

6.  Alanine-scanning mutagenesis of Bacillus subtilis trp RNA-binding attenuation protein (TRAP) reveals residues involved in tryptophan binding and RNA binding.

Authors:  M Yang; X p Chen; K Militello; R Hoffman; B Fernandez; C Baumann; P Gollnick
Journal:  J Mol Biol       Date:  1997-08-01       Impact factor: 5.469

7.  Expansion and deletion of CTG repeats from human disease genes are determined by the direction of replication in E. coli.

Authors:  S Kang; A Jaworski; K Ohshima; R D Wells
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

8.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

9.  Full-length myotonin protein kinase (72 kDa) displays serine kinase activity.

Authors:  L Timchenko; W Nastainczyk; T Schneider; B Patel; F Hofmann; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  7 in total

Review 1.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

Review 2.  Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.

Authors:  A J Marian; L Salek; S Lutucuta
Journal:  Minerva Med       Date:  2001-12       Impact factor: 4.806

3.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

Authors:  J W Miller; C R Urbinati; P Teng-Umnuay; M G Stenberg; B J Byrne; C A Thornton; M S Swanson
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 4.  Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.

Authors:  Laura P W Ranum; John W Day
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 5.  Genetic determinants of cardiac hypertrophy.

Authors:  Ali J Marian
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

Review 6.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

7.  Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1.

Authors:  Qi Yin; Hongye Wang; Na Li; Yifu Ding; Zhenfei Xie; Lifang Jin; Yan Li; Qiong Wang; Xinyi Liu; Liuqing Xu; Qing Li; Yongjian Ma; Yanbo Cheng; Kai Wang; Cuiqing Zhong; Qian Yu; Wei Tang; Wanjin Chen; Wenjun Yang; Fan Zhang; Chen Ding; Lan Bao; Bin Zhou; Ping Hu; Jinsong Li
Journal:  Cell Res       Date:  2019-12-18       Impact factor: 25.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.